Hualan Biological Vaccine (SZSE:301207) Could Be A Buy For Its Upcoming Dividend
Hualan Biological Vaccine (SZSE:301207) Could Be A Buy For Its Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Hualan Biological Vaccine Inc. (SZSE:301207) is about to go ex-dividend in just couple of days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Thus, you can purchase Hualan Biological Vaccine's shares before the 14th of June in order to receive the dividend, which the company will pay on the 14th of June.
一些投资者依赖分红派息增加自己的财富。如果你是其中一位分红派息投资者,你可能会想知道华兰生物疫苗Inc. (SZSE:301207)将于几天内开始除息。除息日是比登记日提前一天的交易日,即股东在该交易日之前完成的任何交易才有资格享受派息。除息日很重要,因为股票的任何交易在登记日之前必须完成才能享有分红。因此,为了获得华兰生物疫苗的分红,你可以在6月14日之前购买股票,公司将在6月14日支付分红。
The company's next dividend payment will be CN¥0.60 per share. Last year, in total, the company distributed CN¥0.60 to shareholders. Looking at the last 12 months of distributions, Hualan Biological Vaccine has a trailing yield of approximately 3.2% on its current stock price of CN¥18.72. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to investigate whether Hualan Biological Vaccine can afford its dividend, and if the dividend could grow.
该公司的下一个派息额将为每股CN¥0.60。去年,该公司向股东派发了总计CN¥0.60的分红派息。从过去12个月的派发情况来看,华兰生物疫苗的股息率约为当前股价CN¥18.72的3.2%。分红对许多股东来说是一项重要的收入来源,但业务的健康状况对于维持分红至关重要。因此,我们需要调查华兰生物疫苗是否能够承担得起它的分红派息,并且分红派息是否可以增长。
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Fortunately Hualan Biological Vaccine's payout ratio is modest, at just 45% of profit. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. What's good is that dividends were well covered by free cash flow, with the company paying out 17% of its cash flow last year.
分红派息通常来自公司盈利。如果公司支付的分红超过其获得的利润,那么该分红可能不可持续。幸运的是,华兰生物疫苗的支付比率很适中,仅为利润的45%。话虽如此,即使高利润公司有时也可能无法产生足够的现金支付分红,这就是为什么我们应该始终检查分红是否由自由现金流覆盖的原因。好的是,去年的自由现金流足以支付分红,公司支付了其现金流的17%。
It's positive to see that Hualan Biological Vaccine's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
能够看到华兰生物疫苗的股息既得到了利润的支持,又得到了现金流的支持,这通常意味着分红是可持续的,而较低的支付比率通常表明在分红被减少之前,有更大的安全边际。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
点击此处查看公司的支付比率以及未来分红的分析师预期。
Have Earnings And Dividends Been Growing?
收益和股息一直在增长吗?
Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. That's why it's comforting to see Hualan Biological Vaccine's earnings have been skyrocketing, up 22% per annum for the past five years. Earnings per share have been growing very quickly, and the company is paying out a relatively low percentage of its profit and cash flow. Companies with growing earnings and low payout ratios are often the best long-term dividend stocks, as the company can both grow its earnings and increase the percentage of earnings that it pays out, essentially multiplying the dividend.
在公司实现可持续盈利增长的股票中,常常是最好的分红机会,因为在收益增长时提高分红更容易。如果企业进入低迷期并削减分红,公司的价值可能会急剧下降。因此,看到华兰生物疫苗的盈利一直在飙升,过去五年的年均增长率为22%,这是令人欣慰的。每股收益增长非常迅速,公司支付的利润和现金流相对较低。拥有增长的盈利和低支付比率的公司通常是最好的长期分红股票,因为公司既可以增长其收益,又可以增加其支付的收益百分比,从而间接实现分红增值。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Since the start of our data, two years ago, Hualan Biological Vaccine has lifted its dividend by approximately 112% a year on average. It's great to see earnings per share growing rapidly over several years, and dividends per share growing right along with it.
衡量公司分红前景的另一个关键方法是测量其历史分红增长率。自我们收集数据以来,华兰生物疫苗的年平均分红增长率约为112%。看到每股收益在多年来迅速增长,并且每股分红随之增长,这是一个好兆头。
The Bottom Line
还有一件事需要注意的是,我们已经确定了上海医药的2个警告信号,了解这些信号应该成为你的投资过程的一部分。
From a dividend perspective, should investors buy or avoid Hualan Biological Vaccine? Hualan Biological Vaccine has been growing earnings at a rapid rate, and has a conservatively low payout ratio, implying that it is reinvesting heavily in its business; a sterling combination. There's a lot to like about Hualan Biological Vaccine, and we would prioritise taking a closer look at it.
从分红的角度来看,投资者应该买还是避开华兰生物疫苗?华兰生物疫苗的盈利率快速增长,并且支付比率相对较低,这表明它在大量重新投资业务; 极佳组合。华兰生物疫苗有很多令人满意的地方,我们将优先考虑更仔细地研究它。
So while Hualan Biological Vaccine looks good from a dividend perspective, it's always worthwhile being up to date with the risks involved in this stock. For example, we've found 1 warning sign for Hualan Biological Vaccine that we recommend you consider before investing in the business.
因此,尽管从分红的角度来看华兰生物疫苗看起来不错,但始终要了解该股票涉及的风险是值得的。例如,我们发现了华兰生物疫苗的一个警示信号,建议您在投资该业务之前考虑该信号。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般来说,我们不建议仅仅购买第一个股息股票。下面是一个经过策划的有趣的、股息表现良好的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。